GB
GT Biopharma Inc
🇺🇸XNAS.GTBPUnited StatesHealthcare
$8.00USDdown -1.05 (-11.6%)OpenDelayed3:30 PM
Price$8.00-1.05 (-11.6%)
Profile
- Healthcare
- Biotechnology
- United States
Identity
- Exchange
- Nasdaq . XNAS
- Type
- Stock
- ISIN
- US36254L3087
- CUSIP
- 36254L209
Company
- Employees
- 1
- Headquarters
- San Francisco, United States
- Website
- https://www.gtbiopharma.com
- CEO
- Mr. Michael Martin Breen L.L.B.
Market
- Shares outstanding
- 1.8M
- Market cap
- $14.44M
Highlights
- Market cap
- $16.33M
- EPS LTM
- -$12.24calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -0.65calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- 32.06%
Fundamentals (LTM)
- Revenue
- $00%unchanged year on year
- Net income
- -$22.08M+42.09%up year on year
- Gross margin
- Not reported
- Free cash flow
- -$14.43M-38.43%down year on year
Other listings
This company is not listed on any other exchange we cover.
These are the venues Finzer covers, not every venue that exists.
Business summary
No company summary reported yet.